Named Bioactive Compounds · Compound
Silybin
Strong Evidencecompound
Hermetica Superfood Encyclopedia
Silybin is the most bioactive flavonolignan compound in milk thistle extract, comprising 50-70% of silymarin complex. It functions as a potent hepatoprotective agent by stabilizing hepatocyte membranes and reducing oxidative stress through antioxidant pathways.
Silybin (also known as silibinin) is the major active flavonolignan constituent of silymarin, a standardized extract from the seeds of the milk thistle plant (Silybum marianum), a thistle native to the Mediterranean region. It is extracted via solvent-based methods from the plant's ripe seeds followed by purification, with standardized extracts containing 70-80% flavonolignans, of which silybin comprises about 50-60%.
Large Phase II trials in NASH patients (NCT00680407, PMID: 31536511; NCT02006498, PMID: 28419855) using 420-2100 mg/day silymarin showed no significant improvement in primary endpoints, though a meta-analysis (PMID: 29245314) found modest transaminase reductions. A triple-blind RCT in breast cancer patients (PMID: 33861657) suggested potential hepatoprotective effects during chemotherapy.
Clinically studied oral doses range from 420-2100 mg/day of standardized silymarin extract (containing ~70% flavonolignans). Common regimens include: NASH treatment 420-700 mg/day or 700 mg three times daily; chemotherapy support 140 mg three times daily; chronic liver disease 160-360 mg/day of silybin or phytosome formulations. Consult a healthcare provider before starting any new supplement.
Silybin is a pure bioactive flavonolignan compound, not a whole food, and therefore has no meaningful macronutrient, vitamin, mineral, or fiber profile in the traditional nutritional sense. Key compositional details: Silybin is the primary active constituent (~50-70%) of silymarin, the standardized extract from milk thistle (Silybum marianum) seeds. It exists as two diastereomers: Silybin A and Silybin B, with Silybin B generally showing greater biological activity. Molecular weight: 482.44 g/mol. As a flavonolignan, it combines a flavonoid (taxifolin) and a lignan (coniferyl alcohol) moiety. Typical therapeutic doses studied range from 94 mg to 576 mg/day of silybin equivalents. Bioavailability is a significant limiting factor: conventional silybin has poor oral bioabsorption (~0.73-1% in some models) due to low water solubility and limited intestinal permeability. Enhanced delivery forms show markedly improved bioavailability: Silybin-phosphatidylcholine complex (Siliphos/IdB 1016) demonstrates 4-10x greater absorption compared to standard silybin; nanoparticle and phytosome formulations further improve plasma concentrations. Peak plasma concentration (Cmax) in phosphatidylcholine complex formulations reached approximately 0.5-1.0 µg/mL at doses of 360 mg. Silybin undergoes hepatic phase II conjugation (glucuronidation and sulfation) and is primarily excreted via bile. No caloric contribution is expected at therapeutic doses.
Silybin stabilizes hepatocyte cell membranes by binding to phospholipids and preventing lipid peroxidation. It activates nuclear factor erythroid 2-related factor 2 (Nrf2) pathways to enhance antioxidant enzyme production including glutathione peroxidase and superoxide dismutase. The compound also inhibits nuclear factor kappa B (NF-κB) activation, reducing inflammatory cytokine production in liver tissue.
A meta-analysis of 8 randomized controlled trials demonstrated silybin's efficacy in non-alcoholic fatty liver disease, reducing AST levels by 6.57 U/L and ALT levels by 9.16 U/L compared to placebo. One RCT in breast cancer patients showed reduced hepatic involvement on ultrasonography during chemotherapy treatment. Evidence quality is moderate for liver enzyme reduction but preliminary for chemotherapy-induced hepatotoxicity prevention. Most studies used silybin-phosphatidylcholine complexes at doses ranging from 376-800mg daily.
Silybin is generally well-tolerated with mild gastrointestinal side effects including nausea, diarrhea, and abdominal discomfort reported in less than 5% of users. It may enhance the absorption of certain medications by inhibiting P-glycoprotein transporters, potentially increasing drug concentrations. Silybin can interact with diabetes medications by enhancing glucose uptake, requiring blood sugar monitoring. Safety during pregnancy and lactation has not been established, so use should be avoided in these populations.
